;

Search Results:

Showing of 50

CLINICAL TRIAL17263

Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18430

Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18346

Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL17790

A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18365

Preliminary Evaluation of an Internet-Assisted Cognitive Behavioral Intervention for Targeted Therapy Fatigue

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18217

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18156

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL17814

Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL19001

A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Myeloma (MM)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18891

A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18521

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications

Cancer Type: Multiple

View Trial Details

CLINICAL TRIAL18950

A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18630

Phase 1/2 Investigator Sponsored Study of Selinexor in Combination with High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18926

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19079

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19093

Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19230

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib,and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details